378 related articles for article (PubMed ID: 31164317)
1. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
[TBL] [Abstract][Full Text] [Related]
2. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
3. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.
Kim TH; Woo S; Yoon SH; Halpenny DF; Han S; Suh CH
AJR Am J Roentgenol; 2019 Nov; 213(5):1059-1072. PubMed ID: 31414902
[No Abstract] [Full Text] [Related]
4. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
[TBL] [Abstract][Full Text] [Related]
5. Imaging Features and Metastatic Patterns of Advanced
Mendoza DP; Lin JJ; Rooney MM; Chen T; Sequist LV; Shaw AT; Digumarthy SR
AJR Am J Roentgenol; 2020 Apr; 214(4):766-774. PubMed ID: 31887093
[No Abstract] [Full Text] [Related]
6. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
7. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
8. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
[TBL] [Abstract][Full Text] [Related]
9. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
Woo JH; Kim TJ; Kim TS; Han J
Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
[TBL] [Abstract][Full Text] [Related]
10. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?
Halpenny DF; Riely GJ; Hayes S; Yu H; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2014 Nov; 86(2):190-4. PubMed ID: 25312988
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer.
Wang X; Chen S; Emerson RE; Wu HH; Cramer HM; Curless K; Chang HY; Zhang S; Randolph ML; Cheng L
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):119-124. PubMed ID: 30688675
[TBL] [Abstract][Full Text] [Related]
16. Small-cell transformation of
Balla A; Khan F; Hampel KJ; Aisner DL; Sidiropoulos N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29317428
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
[TBL] [Abstract][Full Text] [Related]
18. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
19. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
20. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
